EUVIMEDEUVIMED entdecken
Open Access

Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation

Sukrit Srivastava iD, Sonia Verma iD, Mohit Kamthania iD, Rupinder Kaur iD, Ruchi Kiran Badyal iD, Ajay Kumar Saxena iD, Ho-Joon Shin iD, Michael Kolbe iD, Kailash C Pandey iD

JMIR Bioinformatics and Biotechnology · 2020

DOI: 10.2196/19371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIR Bioinformatics and Biotechnology, 2020. Verfasst von Sukrit Srivastava und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infection Biology Group, Department of Biotechnology, Mangalayatan University, Aligarh, India. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The novel coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to the ongoing 2019-2020 pandemic. SARS-CoV-2 is a positive-sense single-stranded RNA coronavirus. Effective countermeasures against SARS-CoV-2 infection require the design and development of specific and effective vaccine candidates.

Objective

To address the urgent need for a SARS-CoV-2 vaccine, in the present study, we designed and validated one cytotoxic T lymphocyte (CTL) and one helper T lymphocyte (HTL) multi-epitope vaccine (MEV) against SARS-CoV-2 using various in silico methods.

Methods

Both designed MEVs are composed of CTL and HTL epitopes screened from 11 structural and nonstructural proteins of the SARS-CoV-2 proteome. Both MEVs also carry potential B-cell linear and discontinuous epitopes as well as interferon gamma–inducing epitopes. To enhance the immune response of our vaccine design, truncated (residues 10-153) Onchocerca volvulus activation-associated secreted protein-1 was used as an adjuvant at the N termini of both MEVs. The tertiary models for both the designed MEVs were generated, refined, and further analyzed for stable molecular interaction with toll-like receptor 3. Codon-biased complementary DNA (cDNA) was generated for both MEVs and analyzed in silico for high level expression in a mammalian (human) host cell line.

Results

In the present study, we screened and shortlisted 38 CTL, 33 HTL, and 12 B cell epitopes from the 11 protein sequences of the SARS-CoV-2 proteome. Moreover, the molecular interactions of the screened epitopes with their respective human leukocyte antigen allele binders and the transporter associated with antigen processing (TAP) complex were positively validated. The shortlisted screened epitopes were utilized to design two novel MEVs against SARS-CoV-2. Further molecular models of both MEVs were prepared, and their stable molecular interactions with toll-like receptor 3 were positively validated. The codon-optimized cDNAs of both MEVs were also positively analyzed for high levels of overexpression in a human cell line.

Conclusions

The present study is highly significant in terms of the molecular design of prospective CTL and HTL vaccines against SARS-CoV-2 infection with potential to elicit cellular and humoral immune responses. The epitopes of the designed MEVs are predicted to cover the large human population worldwide (96.10%). Hence, both designed MEVs could be tried in vivo as potential vaccine candidates against SARS-CoV-2.

Schlagwörter

Stichwörter der Autor:innen

COVID-19coronavirusepitopehuman transporter associated with antigen processing (TAP)immunoinformaticsmolecular docking, molecular dynamics simulationmultiepitope vaccinesevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)toll-like receptor (TLR)

Autor:innen und Institutionen

  • Infection Biology Group, Department of Biotechnology, Mangalayatan University, Aligarh, India.
  • Molecular Medicine Laboratory, School of Life Science, Jawaharlal Nehru University, New Delhi, India.
  • Parasite-Host Biology Group, Protein Biochemistry and Engineering Lab, ICMR-National Institute of Malaria Research, New Delhi, India.
  • Department of Biotechnology, Institute of Applied Medicines and Research, Ghaziabad, India.
  • Department of Chemistry, Guru Nanak Dev University, Amritsar, India.
  • Department of Economics, Mangalayata University, Aligarh, India.

ORCID-Profile: Sukrit Srivastava, Sonia Verma, Mohit Kamthania, Rupinder Kaur, Ruchi Kiran Badyal, Ajay Kumar Saxena, Ho-Joon Shin, Michael Kolbe, Kailash C Pandey

Zitieren

APA

Srivastava, S., Verma, S., Kamthania, M., Kaur, R., Badyal, R. K., Saxena, A. K., Shin, H. J., Kolbe, M., & Pandey, K. C. (2020). Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation. JMIR Bioinformatics and Biotechnology. https://doi.org/10.2196/19371

Vancouver

Srivastava S, Verma S, Kamthania M, Kaur R, Badyal RK, Saxena AK, et al. Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation. JMIR Bioinformatics and Biotechnology. 2020. doi:10.2196/19371

BibTeX
@article{Srivastava2020,
  author = {Srivastava, Sukrit and Verma, Sonia and Kamthania, Mohit and Kaur, Rupinder and Badyal, Ruchi Kiran and Saxena, Ajay Kumar and Shin, Ho-Joon and Kolbe, Michael and Pandey, Kailash C},
  title = {Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation},
  journal = {JMIR Bioinformatics and Biotechnology},
  year = {2020},
  doi = {10.2196/19371}
}
Kostenlos starten →